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Abstract
Purpose To examine the effect of nepafenac, a
selective cyclooxygenase-2 (COX-2) inhibitor,
on the proliferation rate of two human
retinoblastoma (Rb)cell lines.
Methods Two human Rb cell lines (WERI-RB
and Y79) were cultured. COX-2 expression in
these cell lines was verified by
imunocytochemical analysis of cytospin
sections and Western blotting. An MTT-based
proliferation assay was used to compare Rb
cell growth with and without amfenac, the
active metabolite of nepafenac. The averaged
results per condition were recorded. The
Student’s t-test was used to compare results
from the cells cultured with and without
amfenac.
Result The Y79 cell line showed a higher
proliferative rate than the WERI-RB cell line.
Both cell lines were negative for COX-2
expression by immunocytochemical analysis;
however, both cell lines were positive for
COX-2 expression by Western blot. When
amfenac was added to both of the cell lines, a
statistically significant reduction in
proliferation was observed in both cell lines.
The two Rb cell lines were positive for COX-2
only in the Western blot, indicating that they
probably express low levels of COX-2, which
was undetectable by immucytochemical
analysis.
Conclusion The selective, anti-COX-2
molecule amfenac inhibited proliferation of
both tested Rb cell lines. Further trials should
be undertaken to study the effect of selective
COX-2 inhibitors on Rb.
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Introduction
Retinoblastoma (Rb) is the most common
malignant intraocular tumour in children and
overall, the most common retinal tumour.1 Rb is
a unique human disease characterized by a
concentric arrangement of proliferating viable
cells forming sleeves around blood vessels. At
the periphery of the sleeves, the cells become
necrotic. The growth rate of Rb apears to be
more dependent on the ability of the tumour to
induce neovascularization than on the inherent
growth rate of the neoplastic cells.2
There is published evidence that
cyclooxygenase-2 (COX-2)-derived
prostaglandins contribute to tumour growth by
inducing newly formed blood vessels
(neoangiogenesis) that sustain tumour cell
viability and growth.3 Previous publications
have demonstrated COX-2 expression in Rb
specimens and have suggested a possible
relationship between the expression of COX-2
and the genesis of this tumour.4–6
COX-2 is a prostaglandin synthetase involved
in inflammatory processes, growth, and
progression of a variety of human cancers as
well as possible immune responses.4,7 COX-2
contributes to tumorigenesis and the malignant
phenotype of tumour cells through several
mechanisms such as the increase in production
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of prostaglandins, the conversion of procarcinogens to
carcinogens, the inhibition of apoptosis, the promotion of
angiogenesis, the increase in the invasiveness of cancer
cells, and the modulation of inflammation and
immunoresponse.8,9 Studies have shown in colorectal
cancer that overexpresses COX-2, there is a 40–50%
decrease in mortality among patients taking COX-2
inhibitors.10,11
The purpose of this study is to examine the effect of
nepafenac, a selective COX-2 inhibitor, on the in vitro
proliferation rate of two human Rb cell lines.
Materials and methods
Cell culture
Two human Rb cell lines were used for this study
(WERI-RB and Y79, American Type Culture Collection,
Manassas, VA, USA). These cell lines were cultured in
RPMI-1640 medium (500 ml) (Invitrogen Life
Technologies, Burlington, Ontario, Canada),
supplemented with 10% by volume heat-inactivated fetal
bovine serum (FBS; Invitrogen), 1250mg of fungizone
(Invitrogen), and 50 000 U of penicillin–streptomycin
(Invitrogen). Cell pellets were resuspended to a dilution
of 5 103 cells/ml and cytospin slides were made. The
slides were stored at 201C until used.
Immunocytochemistry
The cytospin slides were removed from 201C and left at
room temperature overnight before being fixed with 2%
paraformaldehyde for 30 min. The paraformaldehyde-
fixed samples were then tested for COX-2 expression by
immunocytochemical analysis using a monoclonal
mouse anti-COX-2 antibody (Zimed Laboratories, San
Francisco, CA, USA; clone COX 229) at a dilution of 1 : 50.
Western blot analysis
Protein samples from two cell lines were prepared using
100ml/106 cells of 2 electrophoresis sample buffer
(250 mM TRIS pH 6.8, 4% SDS, 10% glycerol, 0.006%
bromophenol blue, 2% b mercaptoethanol), which was
then boiled for 5 min. Proteins were separated on 12%
SDS-Page gel and transferred to a polyvinylidene
difluoride (PVDF) membrane overnight. (Amersham
Bioscience, Piscataway, NJ, USA).
The membrane was blotted for a specific antibody
according to Proto Blot for Western blot alkaline
phosphatase system (Promega Corporation, Nepean,
Ontario, Canada). The primary antibody monoclonal
mouse anti-human COX-2 (clone 229-Zymed, Labo-
ratories, San Francisco, CA, USA) was used at the
concentration of 3mg/ml. The secondary antibody
(1 : 8000) goat anti-mouse alkaline phosphatase-conjugated
(Sigma-Aldrich, Oakville, Ontario, Canada) was used to
visualize the proteins on the membrane. Cell lysate from
macrophages stimulated with interferon gamma and LPS
(Transduction Laboratories, BD Biosciences, San Diego,
CA, USA) was used as a positive control.
Proliferation assay
An in vitro toxicology assay kit, MTT based, was used to
evaluate the quantitative response by a cell population to
external factors, whether due to an increase in cell
growth, no effect or to a decrease in growth due to
necrosis or apoptosis. This assay was used to compare Rb
cell growth with and without amfenac, the active
metabolite of the anti-COX-2 medication nepafenac
(Alcon Laboratories Inc, Fort Worth, TX, USA). Briefly, all
cell lines were seeded at a concentration of 5000 cells per
well into a 96-well plate (Beckton Dickenson Labware,
Bedford, MA, USA). Amfenac was added to the
experimental wells of each cell line at the recommended
50% inhibitory concentration (IC50) of 150 nM, while
RPMI was added to the control wells. Cells were allowed
to incubate for 48 h at 371C, in a humidified 5% CO2-
enriched atmosphere. The mitochondrial activity was
assayed using the MTT assay done in six wells per
condition. The entire assay was repeated three times. The
average results per cell line were recorded for each
condition. The Student’s t-test was used to compare the
in vitro proliferation rates of Rb cell lines cultured with
and without amfenac.
Results
The two cell lines were negative for COX-2 expression by
immunocytochemical assay. Both cell lines were shown
to be positive for COX-2 expression when using Western
blot (Figure 1).
The Y79 cell line showed a higher proliferative rate
than the WERI-RB cell line with an average absorption of
0.9170.09 compared to 0.5770.08 (Figure 2). When
amfenac was added to both of the cell lines, a statistically
significant reduction in proliferation was observed in
both of them (Pr0.005). The Y-79 cell line revealed
however a more significant decrease in proliferation
when amfenac was added (Po0.001). The Y79 cell line
also had a decrease in absorption to 0.770.07, while the
WERI-RB cell line showed a decrease to 0.4770.03.
Discussion
The presence of COX-2 in the retina as well as the
antiangiogenic effects of selective COX-2 inhibition in
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both developmental and pathologic retinal angiogenesis
has been demonstrated.12 Anti-COX-2 agents have
shown promising antitumour efficacy in lung cancer and
a large variety of solid tumours that rely on COX-2-
related mechanisms for growth and survival.13 COX-2
protein overexpression has been reported to correlate
with decreased survival in patients with cervical cancer
after treatment with radiotherapy14 and, as previously
mentioned, a possible relationship between the
expression of COX-2 and the genesis of Rb has been
suggested.4–6
According to Chevez-Barrios et al (2000), the same Rb
cell lines used in this study (WERI-RB and Y79) have
very distinctive behaviour as observed in a murine
animal model. When inoculated in these animals, the
Y-79 cell line generated aggressive tumours with invasive
and metastatic potential. On the other hand, the WERI-
RB cell line gave rise to localized tumours that only
invaded the anterior structures of the eye without
extraocular spread or metastasis.15 In the study herein,
the proliferation rate observed in these two cell lines
supported that publication, confirming a more aggressive
potential of the Y-79 cell line.
COX-2 expression in Rb specimens has been reported
in both well and poorly differentiated tumours.
However, a more diffuse and pronounced reaction was
observed in the undifferentiated tumours.4 Considering
the reported findings, it is understandable that amfenac
presented a more accentuated inhibitory effect when
added to the more aggressive cell line with the higher
proliferation rate, which translates into a more
undifferentiated cell type.
The relevance of COX-2 overexpression in Rb has not
been determined and neither has a potential clinical use
in patients. There are only two publications investigating
COX-2 expression in Rb and neither of them discusses
the possibility of a clinical application such as using an
anti-COX-2 medication to control tumour proliferation4,6
possibly in conjunction with chemotherapeutics.
According to the findings herein, the use of an anti-COX-2
compound considerably inhibited the proliferation of
both Rb cell lines. Extrapolating this finding to the
clinical practice can make an important point. If this
prostaglandin has the same behaviour in Rb as in other
tumours,7–9 it is possible to speculate a future clinical use
of amfenac in patients with Rb, regardless of the
impossibility of biopsying these tumours for COX-2
immunoassay due to potential spreading.
Many studies have shown that anti-COX-2
medications induce apoptosis in various cancer cells by
different mechanisms depending on the cell type.16 The
precise cellular target(s) of these COX-independent
effects have not been elucidated.17 The in vitro
antiproliferative effect of anti-COX-2 drugs on cancer cell
lines has been determined. This effect was found to be
similar regardless of the expression of COX-2 in
epithelial cell lines. This effect also extends to COX-2-
negative breast, cervix, prostate, and ovarian carcinoma
cell lines.16,17 While the two Rb cell lines used in this
experiment were found to express COX-2 by Western
blot, they were negative when assayed by
Figure 1 Western blot of COX-2 expression in two Rb cell lines.
Lane 1 is the marker, lane 2 is the positive control, lane 3 is the
WERY RB cell line, and lane 4 is the Y79 cell line. Arrows
indicate bands that have stained positive for COX-2 protein in
the two RB cell lines.
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Figure 2 Proliferation rate of two retinoblastoma cell lines
(WERI-RB and Y79) with and without amfenac, the active
metabolite of nepafenac, an anti-COX-2 medication.
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immunocytochemistry. This probably indicates that both
cell lines expressed low levels of COX-2, which were not
detectable using immunocytochemical methods.
Therefore, the use of selective COX-2 inhibitors, such as
amfenac, may be useful even in cases where tumours
were not seen to express COX-2 in
immunocytochemistry.
Recently, there has been much discussion over the
safety of systemic COX-2 inhibitors, most notably
celecoxib.18 In our study we used amfenac, the active
metabolite of nepafenac, which has been formulated to
be administered as eye drops and therefore likely
presents a more local treatment to the eye than oral
medications.19
In conclusion, the selective anti-COX-2 molecule
amfenac inhibited the proliferation of both tested Rb cell
lines despite the fact that both cell lines were negative for
COX-2 expression. This may indicate that a secondary
pathway is involved in the effect of amfenac upon
cellular proliferation. Further trials should be undertaken
to study the effect of selective COX-2 inhibitors on Rb.
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